PK-PD Tox. & Formulation Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India; Product Development Cell-II, National Institute of Immunology, New Delhi, India.
Product Development Cell-II, National Institute of Immunology, New Delhi, India.
Mater Sci Eng C Mater Biol Appl. 2019 May;98:764-771. doi: 10.1016/j.msec.2019.01.026. Epub 2019 Jan 8.
The present study demonstrated the development of gemcitabine and betulinic acid co-encapsulated PLGA-PEG polymer nanoparticles for enhancing the chemotherapeutic response. This combinatorial PLGA-PEG nanoparticle was formulated using double emulsion and had size <200 nm. The developed nanoparticles were characterized using dynamic light scattering and transmission electron microscopy for their size and shape, respectively. The in vitro release of the drugs from combinatorial nanoparticles was predominantly followed by Fickian diffusion phenomenon. Study on hemocompatibilty approved the administration of this combinatorial nanoparticle for animal study. In vitro cytotoxicity study on Panc1 cells using MTT assay, reactive oxygen species production and cellular apoptotic assay demonstrated that combinatorial nanoparticle was more cytotoxic compared to native drugs solution. Furthermore, the combinatorial nanoparticle suppressed tumor growth more efficiently in Ehrlich (solid) tumor model than the native gemcitabine and betulinic acid at the same concentrations. These findings indicated that PLGA-PEG nanoparticle might be used to co-deliver multiple chemotherapeutic drugs with different properties for enhancing antitumor efficacy.
本研究旨在开发吉西他滨和白桦酸共包封于 PLGA-PEG 聚合物纳米粒中,以增强化疗反应。这种组合的 PLGA-PEG 纳米粒是通过双重乳液法制备的,粒径<200nm。使用动态光散射和透射电子显微镜分别对纳米粒的粒径和形态进行了表征。药物从组合纳米粒中的体外释放主要遵循菲克扩散现象。对血液相容性的研究证实了这种组合纳米粒可用于动物研究。使用 MTT 法、活性氧产生和细胞凋亡测定法对 Panc1 细胞进行体外细胞毒性研究表明,与天然药物溶液相比,组合纳米粒的细胞毒性更高。此外,在相同浓度下,组合纳米粒在 Ehrlich(固)肿瘤模型中比天然吉西他滨和白桦酸更有效地抑制肿瘤生长。这些发现表明,PLGA-PEG 纳米粒可用于共递输送具有不同性质的多种化疗药物,以增强抗肿瘤疗效。
Mater Sci Eng C Mater Biol Appl. 2019-1-8
ACS Appl Mater Interfaces. 2016-12-2
World J Gastroenterol. 2010-2-28
J Photochem Photobiol B. 2017-5-22
ACS Omega. 2025-7-24
Mol Cancer. 2025-7-24
Pharmaceutics. 2025-6-4
Int J Nanomedicine. 2024-12-29
Biomedicines. 2024-5-24
Theranostics. 2023